jyongbio.com - MENS Company profit before taxes, interest and amortization
The specific nature of the botanical R&D cycle complicates drug releases, yet success in urology and expense control maintain the stability of Jyong Biotech Ltd (MENS). Absolute EBITDA reflects current cash flow dynamics, where the parameter value reaches 0.00. These figures are based on the development of safe plant-based medications for prostate treatment without side effects.
Summary analytical data breakdowns for Jyong Biotech (MENS)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Jyong Biotech Ltd|MENS - Long-Term Debt to Equity|Short-Term Loans to Capital Ratio Jyong Biotech Limited|MENS - Company Total Debt|Debts to Book Value Jyong Biotech|MENS - Company Long-Term Debt|Short-Term Debt Jyong Biotech|Immediate Liquidity Ratio jyongbio.com
- earnings and market ratios statistics:
MENS - Net Profit|Projected Net Profit Jyong Biotech Ltd|MENS - Price to Earnings Ratio|Future Price to Earnings Multiple jyongbio.com|MENS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jyong Biotech|MENS - Operating profit EBITDA|Net earnings per share for the last four quarters Jyong Biotech|MENS - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months jyongbio.com|MENS - Net earnings per share growth this year|Projected earnings per share increase next year Jyong Biotech Ltd
- sales revenue and business income indicators:
Fundamental company valuation:Jyong Biotech Ltd
This indicator tracks daily cash flow from core operations before depreciation, interest, and taxes, allowing for an assessment of the business's actual operational efficiency. By analyzing the level of net operating income before depreciation, an investor can see the ability of Jyong Biotech Ltd (MENS) to fund its R&D team and hire compliance specialists using its own resources without increasing its debt load.
Competitors of Jyong Biotech Ltd (MENS)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|LGND: Operating profit EBITDA|Amneal Pharmaceuticals, Inc. - Income before deduction of interest, taxes and amortization|PRGO (Perrigo Company) - Operating profit EBITDA|Profit before interest, taxes and amortization Alvotech Biopharmaceuticals ALVO|Profit before payment of interest, taxes and amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization ANI Pharmaceuticals, Inc. ANIP|Company profit before taxes, interest and amortization MNKD (MannKind Corp)|AMPH: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Pacira Corp|ARS Pharmaceuticals (SPRY) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization theravance.com (TBPH)|Profit before payment of interest, taxes and amortization Aquestive Therapeutics, Inc.|Operating profit before amortization SCPH (scPharma)|Operating profit EBITDA TECX|Tonix Pharmaceuticals Holding (TNXP) - Operating profit before depreciation charges|China SXT Pharmaceuticals, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization EPRX|BioHarvest Sciences Inc. - Operating profit EBITDA|EXOZ: Profit before payment of interest, taxes and amortization|ORMP: Operating profit EBITDA|ENTX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization MindWalk Holdings|Profit before interest, taxes and amortization abvcpharma.com ABVC|Operating profit before deduction of amortization CPIX (Cumberland Pharmaceuticals Inc.)|Company profit before taxes, interest and amortization QNTM|Operating profit EBITDA FGEN (FibroGen Corp)|Telomir Pharmaceuticals Corp (TELO) - Profit before interest, taxes and amortization|Rani Therapeutics Inc - Operating profit EBITDA|Synergy CHC Corp (SNYR) - Operating profit before deduction of amortization|RLYB: Operating profit EBITDA|Lexaria Bioscience Corp. - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization PULM|PTHL: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Aptorum Group Limited (APM)|Profit before payment of interest, taxes and amortization LYRA (lyratherapeutics.com)|Impact BioMedical - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization TNFA (TNF Pharmaceuticals Inc.)|cbdMD Corp - Operating profit EBITDA|PRFX (PainReform Corp) - Operating profit before amortization|altamiratherapeutics.com (CYTO) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization lipella.com|OPTN (OptiNose) - Operating profit EBITDA|Profit before interest, taxes and amortization Pieris Pharmaceuticals Inc PIRS|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|Petros Pharma - Operating profit before amortization|Profit before payment of interest, taxes and amortization Qilian International QLI|Operating income before deduction of amortization acelyrin.com (SLRN)|TFFP - Profit before payment of interest, taxes and amortization
